发明授权
US07910602B2 Pyrazolopyridine derivatives as inhibitors of β-Adrenergic receptor kinase 1
有权
吡唑并吡啶衍生物作为β-肾上腺素能受体激酶1的抑制剂
- 专利标题： Pyrazolopyridine derivatives as inhibitors of β-Adrenergic receptor kinase 1
- 专利标题（中）： 吡唑并吡啶衍生物作为β-肾上腺素能受体激酶1的抑制剂
-
申请号： US11961282申请日： 2007-12-20
-
公开(公告)号： US07910602B2公开(公告)日： 2011-03-22
- 发明人: Henning Steinhagen , Jochen Huber , Kurt Ritter , Bernard Pirard , Kirsten Bjergarde , Marcel Patek , Martin Smrcina , Linli Wei
- 申请人： Henning Steinhagen , Jochen Huber , Kurt Ritter , Bernard Pirard , Kirsten Bjergarde , Marcel Patek , Martin Smrcina , Linli Wei
- 申请人地址： FR Paris
- 专利权人： Sanofi-Aventis
- 当前专利权人： Sanofi-Aventis
- 当前专利权人地址： FR Paris
- 代理机构： Scully, Scott, Murphy and Presser, P.C.
- 代理商 Serena Farquharson-Torres
- 优先权： EP05013774 20050627
- 主分类号： A61K31/44
- IPC分类号： A61K31/44 ; A01N43/42 ; C07D471/02 ; C07D491/02 ; C07D498/02 ; C07D513/02
摘要：
The invention relates to 6-amido substituted pyrazolopyridine derivatives of the formula (I) useful as inhibitors of beta-adrenergic receptor kinase 1 (βARK-1), compositions containing such compounds and their use for the treatment and prevention of chronic heart failure, hypertension, myocardial ischemia and hepatitis C virus (HCV) infections, and for the prevention of opiate addiction.